“vertex-pharmaceuticals” Archives

in
Entry Author Date Location
Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More 11/08/19 National
Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More 10/25/19 National
Vertex Stock Up on Quick FDA OK For 3-Drug Cystic Fibrosis Therapy 10/22/19 Boston
Bio Roundup: PARP Progress, A New Commish, IPO-Palooza & More 10/04/19 National
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone 09/06/19 National
Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes 09/03/19 Boston
White House Floats Canadian Import Plan But Excludes Many Costly Drugs 07/31/19 National
Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More 07/26/19 National
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles 07/25/19 Boston
Vertex Pharma Shells Out $420M to Move Into Muscular Dystrophy 06/07/19 Boston
Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More 05/31/19 National
Vertex Selects Drug Combo, a Potential Therapy for 90% of CF Patients 05/30/19 Boston
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More 05/17/19 National
Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera 05/15/19 Boston
Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More 04/05/19 National
Analysts: Proteostasis Data Are No Boost vs. Vertex in Cystic Fibrosis 03/25/19 Boston
Bio Roundup: Gottlieb Exits, Bristol Defends, Biogen Buys & More 03/08/19 National
Vertex Faces Choice After Second CF Drug Combo Succeeds in Phase 3 03/06/19 Boston
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More 01/25/19 National
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
Vertex Hits Again in CF as First Three-Drug Combo Succeeds in Phase 3 11/27/18 Boston
Eyeing $500M, Moderna Outlines Plans for Biotech’s Biggest IPO Ever 11/09/18 Boston
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More 10/26/18 National
CRISPR Therapeutics, Vertex Get FDA Green Light for Sickle Cell Test 10/10/18 Boston
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More 08/10/18 National
SQZ Biotech Adds $72M as Cell Therapy Investment Keeps Burning Hot 08/08/18 Boston
OUTBio, a Biopharma LGBTQ Group, Grows Fast & Ponders Its Future 07/26/18 Boston
Bluebird’s Upgraded Gene Therapy Shows Promise For Sickle Cell Patients 06/15/18 Boston
Bio Roundup: Wrapping ASCO, Dreaming IPO, Rebooting Axovant & More 06/08/18 National
Vertex CF Competitor Proteostasis Falters, Galapagos Up Next 06/07/18 Boston
Page 1 of 14 next page »